Estamos no ar no ! Saiba mais
141,10 USD
+2,33
1,68%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
140,96
-0,14
0,1%
1 dia
1,68%
5 dias
4,67%
1 mês
0,36%
3 meses
-14,19%
6 meses
-29,96%
No acumulado do ano
-50,13%
1 ano
-55,39%
5 anos
-51,66%
10 anos
258,67%
 

Sobre: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Funcionários: 5.400

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 5,8%
Neutro 92,3%
Negativo 1,9%
Positivo
Zacks Investment Research
há 13 horas
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Insulet (PODD) is a Strong Growth Stock
Neutro
Business Wire
há 4 dias
Insulet Announces Omnipod Discover Now Available in U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover turns critical diabetes data into clear visualizations and personalized insights, giving people with diabetes and their HCPs a shared understanding of.
Insulet Announces Omnipod Discover Now Available in U.S.
Neutro
Business Wire
há 15 dias
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the.
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Positivo
Zacks Investment Research
há 21 dias
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Positivo
MarketBeat
há 21 dias
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet NASDAQ: PODD Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Neutro
Seeking Alpha
há 22 dias
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Neutro
Business Wire
há 28 dias
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About.
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Neutro
Seeking Alpha
mês passado
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Positivo
Zacks Investment Research
mês passado
Here's Why Insulet (PODD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Insulet (PODD) is a Strong Growth Stock
Positivo
Zacks Investment Research
mês passado
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
Gráficos de preços implementados com Lightweight Charts™